<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="9d52f9d2-f66b-4457-8cb7-c48a6e7d076f"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use DAYSEE safely and effectively. See full prescribing information for DAYSEE.<br/>Daysee <sup>TM</sup> [levonorgestrel and ethinyl estradiol tablets USP (0.15 mg/0.03 mg) and ethinyl estradiol tablets USP (0.01 mg)] for oral use<br/>Initial U.S. Approval: 1982</title>
   <effectiveTime value="20250512"/>
   <setId root="a9861412-4e54-4984-b14c-a1dd91d5c946"/>
   <versionNumber value="17"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="089153071" root="1.3.6.1.4.1.519.1"/>
            <name>Lupin Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="675923163" root="1.3.6.1.4.1.519.1"/>
                  <name>LUPIN LIMITED</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="650582310" root="1.3.6.1.4.1.519.1"/>
                        <name>LUPIN LIMITED</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-846" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="58a86925-37d3-45fa-8c1e-f3bebf10eeb5"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250512"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68180-846" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Daysee
</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LEVONORGESTREL AND ETHINYL ESTRADIOL</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="2" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="68180-846-13" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20130410"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="84" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>LEVONORGESTREL AND ETHINYL ESTRADIOL
</name>
                              <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name> LEVONORGESTREL AND ETHINYL ESTRADIOL </name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="0.03" unit="mg"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="423D2T571U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ETHINYL ESTRADIOL</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="423D2T571U" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>ETHINYL ESTRADIOL</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="0.15" unit="mg"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="5W7SIA7YZW" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVONORGESTREL</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="5W7SIA7YZW" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>LEVONORGESTREL</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ANHYDROUS LACTOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CELLULOSE, MICROCRYSTALLINE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CROSCARMELLOSE SODIUM</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C BLUE NO. 1</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C YELLOW NO. 6</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FERRIC OXIDE YELLOW</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM STEARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 400</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="U725QWY32X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POVIDONE K30</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="ANDA091467" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20130410"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="CE" code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLUE">
                                    <originalText>Light blue</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND">
                                    <originalText>round;biconvex</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="PQ" value="6" unit="mm"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="INT" value="1"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">LU;V21</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="7" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>ETHINYL ESTRADIOL
</name>
                              <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name> ETHINYL ESTRADIOL </name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="0.01" unit="mg"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="423D2T571U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ETHINYL ESTRADIOL</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="423D2T571U" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>ETHINYL ESTRADIOL</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C YELLOW NO. 6</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FERRIC OXIDE YELLOW</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ANHYDROUS LACTOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM STEARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CELLULOSE, MICROCRYSTALLINE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="0BZ5A00FQU" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLACRILIN POTASSIUM</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 400</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="ANDA091467" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20130410"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="CE" code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW">
                                    <originalText>mustard</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND">
                                    <originalText>round;biconvex</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="PQ" value="6" unit="mm"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="INT" value="1"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">LU;V22</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA091467" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20130410"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID1">
               <id root="8f9e4ba5-3171-4d27-b519-9fdaf198b2dd"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS</title>
               <text>
                  <paragraph ID="ID2">Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including Daysee, are contraindicated in women who are over 35 years of age and smoke. <content styleCode="bold">[See Contraindications  (4) and Warnings and Precautions (5.1).].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID4">WARNING: CIGARETTE SMOKING AND SERIOUS</paragraph>
                        <paragraph>CARDIOVASCULAR EVENTS</paragraph>
                        <paragraph>See full prescribing information for complete boxed warning.</paragraph>
                        <list listType="unordered" ID="ID5" styleCode="Disc">
                           <item>Daysee is contraindicated in women over 35 years old who smoke.</item>
                           <item>Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID6">
               <id root="904f38f6-e111-4e7b-bc03-32e8ee20d41d"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title>RECENT MAJOR CHANGES</title>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID8">Contraindications, Pregnancy (<linkHtml href="#ID30">4</linkHtml>)                                            Removed 01/2023 </paragraph>
                        <paragraph>Warnings and Precautions, Malignant Neoplasms (<linkHtml href="#ID65">5.11</linkHtml>)                          04/2022</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID9">
               <id root="7d37b218-4da5-46ed-a631-cd3d03f0be06"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID10">Daysee™ is indicated for use by females of reproductive potential to prevent pregnancy. </paragraph>
               </text>
               <effectiveTime value="20230628"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID12">Daysee is a combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive to potential prevent pregnancy. (<linkHtml href="#ID9">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID13">
               <id root="b58406be-db62-4fc3-88eb-a2c00e1816bf"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID15">Take one tablet daily by mouth at the same time every day for 91 days in the order directed on the blister pack. (<linkHtml href="#ID13">2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID16">
                     <id root="546f1cfa-d59f-4440-b97f-520cf43a5c7f"/>
                     <title>2.1 How to Start and Take Daysee</title>
                     <text>
                        <paragraph ID="ID17">Begin Daysee on the first Sunday after the onset of menstruation. If menstruation begins on a Sunday, take the first light blue tablet that day.</paragraph>
                        <paragraph>For each 91-day course, take in the following order:</paragraph>
                        <list listType="ordered" ID="ID18">
                           <item>Start the first <content styleCode="bold">blue tablet </content>on the first Sunday after onset of menstruation. Then take one light blue tablet daily for 84 consecutive days. Use a non-hormonal back-up method of contraception (such as condoms and spermicide) until a light blue tablet has been taken daily for 7 consecutive days.</item>
                           <item>Then take one <content styleCode="bold">mustard </content>tablet for 7 consecutive days. Bleeding should occur during the 7 days that the mustard tablets are taken.</item>
                        </list>
                        <paragraph ID="ID19">Begin the next and all subsequent 91-day cycles without interruption on the same day of the week (Sunday) on which the patient began her first dose of Daysee, following the same schedule: 84 days taking a light blue tablet followed by 7 days taking a mustard tablet. If the patient does not immediately start her next pill pack, instruct her to protect herself from pregnancy by using a non-hormonal back-up method of contraception until she has taken a light blue tablet daily for 7 consecutive days.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Switching to Daysee from another oral hormonal contraceptive or from another contraceptive method (transdermal patch, vaginal ring, injection, intrauterine contraceptive, implant)</content>
                           </content>
                        </paragraph>
                        <paragraph>Start on the Sunday after the patient's next period starts. Use additional non-hormonal contraceptive (such as condoms and spermicide) until the patient has taken a light blue tablet for 7 consecutive days.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Starting Daysee after Abortion or Miscarriage</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">First-trimester</content>
                           </content>
                        </paragraph>
                        <paragraph>Daysee may be started on the Sunday after an abortion or miscarriage. The patient must use additional non-hormonal contraception (such as condoms and spermicide) until the patient has taken a light blue tablet for 7 consecutive days.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Second-trimester</content>
                           </content>
                        </paragraph>
                        <paragraph>Do not start until 4 weeks after a second-trimester abortion or miscarriage, due to the increased risk of thromboembolic disease. Start contraceptive therapy with Daysee following the instructions for women not currently using hormonal contraception. Use additional non-hormonal contraception (such as condoms and spermicide) until the patient has taken a light blue tablet for 7 consecutive days <content styleCode="italics">[see Contraindications (4) and Warnings and Precautions (5.1)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Starting Daysee after Childbirth </content>
                        </paragraph>
                        <paragraph>Do not start until 4 weeks after delivery, due to the increased risk of thromboembolic disease. Start contraceptive therapy with Daysee following the instructions for women not currently using hormonal contraception. Use additional non-hormonal contraception (such as condoms and spermicide) until the patient has taken a light blue tablet for 7 consecutive days <content styleCode="italics">[see Contraindications (4) and Warnings and Precautions (5.1)].</content>
                        </paragraph>
                        <paragraph>If the woman has not yet had a period postpartum, consider the possibility of ovulation and conception occurring prior to use of Daysee <content styleCode="italics">[see Warnings and Precautions (5.1), Use in Specific Populations (8.1)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID20">
                     <id root="ab187751-4737-47a4-8e48-191b99e36f35"/>
                     <title>2.2 Dosing Daysee</title>
                     <text>
                        <paragraph ID="ID21">Take one tablet by mouth at the same time every day. The dosage of Daysee is one light blue tablet daily for 84 consecutive days, followed by one mustard tablet daily for 7 days. To achieve maximum contraceptive effectiveness, Daysee must be taken exactly as directed, in the order directed, and at intervals not exceeding 24 hours. The failure rate may increase when pills are missed or taken incorrectly.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID22">
                     <id root="86877d1a-029b-46c7-903d-f6a40603cc1d"/>
                     <title>2.3 Missed Doses</title>
                     <text>
                        <table ID="ID23" width="624" styleCode="Noautorules">
                           <caption>  Table 1. Instructions for Missed Daysee Tablets </caption>
                           <col width="162"/>
                           <col width="463"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left"> If one light blue tablet is missed<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="left"> Take the missed tablet as soon as possible.<br/> Take the next tablet at the regular time.<br/> Continue taking one tablet a day until the pack is finished. A back-up birth control method is not required if the patient has sex.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> If two light blue tablet in a row are missed<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Take the two missed tablets as soon as<br/> possible, and the next two tablets the next day. Continue taking one tablet a day until the pack is finished. Use additional nonhormonal contraception (such as condoms and spermicide) until tablets have been taken for 7 days after missing tablets.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> If three or more light blue pills in a row are missed<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Throw away the missed pills. Continue taking one tablet every day as indicated on the pack until the pack is finished. Bleeding may occur during the week following the missed tablets. <br/> Use additional nonhormonal contraception (such as condoms and spermicide) until tablets have been taken for 7 days after missing tablets.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> If any of the seven mustard tablets are missed<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Throw away the missed tablets. Continue taking the remaining tablets until the pack is finished. A backup birth control method is not needed.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID24">
                     <id root="edfdf84f-a67a-45d7-8a7e-c258918f15da"/>
                     <title>2.4 Advice in Case of Gastrointestinal Disturbances</title>
                     <text>
                        <paragraph ID="ID25">In case of prolonged vomiting or diarrhea, absorption may not be complete and additional contraceptive measures should be taken.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID26">
               <id root="8cdbaa24-9682-477b-be81-2ff2f8bdae83"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="ID27">Daysee (levonorgestrel and ethinyl estradiol tablets and ethinyl estradiol tablets) are available in Extended-Cycle Tablet Dispensers, each containing a 13-week supply of tablets: 84 light blue tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg ethinyl estradiol, and 7 mustard tablets each containing 0.01 mg of ethinyl estradiol. The light blue tablets are round, biconvex film-coated tablets, debossed with "LU" on one side and "V21" on the other side. The mustard tablets are round, biconvex film-coated tablets debossed with "LU" on one side and "V22" on the other side.</paragraph>
               </text>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID29">Daysee consists of 84 light blue tablets containing 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol, and 7 mustard tablets containing 0.01 mg ethinyl estradiol. (<linkHtml href="#ID26">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID30">
               <id root="d4cbb467-224d-4298-80da-ef18a61458c2"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID31">Daysee is contraindicated in females who are known to have or develop the following conditions:</paragraph>
                  <list listType="unordered" ID="ID32" styleCode="Disc">
                     <item>A high risk of arterial or venous thrombotic diseases. Examples include females who are known to:</item>
                     <item>Smoke, if over age 35 [see Boxed Warnings and Warnings and Precautions (<linkHtml href="#ID36">5.1</linkHtml>)].</item>
                     <item>Have current or history of deep vein thrombosis or pulmonary embolism [see Warnings and Precautions (<linkHtml href="#ID36">5.1</linkHtml>)].</item>
                     <item>Have cerebrovascular disease [see Warnings and Precautions (<linkHtml href="#ID36">5.1</linkHtml>)]</item>
                     <item>Have coronary artery disease [see Warnings and Precautions (<linkHtml href="#ID36">5.1</linkHtml>)].</item>
                     <item>Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (<linkHtml href="#ID36">5.1</linkHtml>)].</item>
                     <item>Have inherited or acquired hypercoagulopathies [see Warnings and Precautions (<linkHtml href="#ID36">5.1</linkHtml>)].</item>
                     <item>Have uncontrolled hypertension or hypertension with vascular disease [see Warnings and Precautions (<linkHtml href="#ID43">5.3</linkHtml>)].</item>
                     <item>Have diabetes mellitus and are over age 35, diabetes mellitus with hypertension or with vascular disease or other end-organ damage, or diabetes mellitus of &gt;20 years duration [see Warnings and Precautions (<linkHtml href="#ID52">5.7</linkHtml>)].</item>
                     <item>Have headaches with focal neurological symptoms, migraine headaches with aura, or over age 35 with any migraine headaches [see Warnings and Precautions (<linkHtml href="#ID54">5.8</linkHtml>)].</item>
                     <item>Current diagnosis of, or history of, breast cancer, which may be hormone sensitive [see Warnings and Precautions (<linkHtml href="#ID65">5.11</linkHtml>)].</item>
                     <item>Liver tumors, acute viral hepatitis, or severe (decompensated) cirrhosis [see WARNINGS AND Warnings and Precautions (<linkHtml href="#ID41">5.2</linkHtml>) and Use in Specific Populations (<linkHtml href="#ID110">8.6</linkHtml>)].</item>
                     <item>Undiagnosed abnormal uterine bleeding [see Warnings and Precautions (<linkHtml href="#ID56">5.9</linkHtml>)]</item>
                     <item>Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID45">5.4</linkHtml>)]. </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID34" styleCode="Disc">
                           <item>A high risk of arterial or venous thrombotic diseases (<linkHtml href="#ID30">4</linkHtml>)</item>
                           <item>Undiagnosed abnormal uterine bleeding (<linkHtml href="#ID30">4</linkHtml>)</item>
                           <item>Breast cancer (<linkHtml href="#ID30">4</linkHtml>)</item>
                           <item>Liver tumors or liver disease, acute viral hepatitis or decompensated cirrhosis (<linkHtml href="#ID30">4</linkHtml>)</item>
                           <item>Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. (<linkHtml href="#ID30">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID35">
               <id root="0edba657-dcb9-4fbe-862f-ebf69ce829be"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID74" styleCode="Disc">
                           <item>Vascular risks: Stop if a thrombotic or thromboembolic event occurs. Stop at least 4 weeks before and through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding. Consider cardiovascular risk factors before initiating in all females, particularly those over 35 years.  (<linkHtml href="#ID36">5.1</linkHtml>, <linkHtml href="#ID47">5.5</linkHtml>)</item>
                           <item>Liver disease: Discontinue if jaundice occurs. (<linkHtml href="#ID41">5.2</linkHtml>)</item>
                           <item>Hypertension: If used in females with well-controlled hypertension, monitor blood pressure and stop if blood pressure rises significantly. (<linkHtml href="#ID43">5.3</linkHtml>)</item>
                           <item>Gallbladder disease : May cause or worsen gallbladder disease. (<linkHtml href="#ID50">5.6</linkHtml>)</item>
                           <item>Adverse carbohydrate and lipid metabolic effects: Monitor glucose in  prediabetic and diabetic women taking Daysee. Consider an alternate contraceptive method for women with uncontrolled dyslipidemias. (<linkHtml href="#ID52">5.7</linkHtml>)</item>
                           <item>Headache: Evaluate significant change in headaches and discontinue if indicated. (<linkHtml href="#ID54">5.8</linkHtml>)</item>
                           <item>Uterine bleeding: May cause irregular bleeding or amenorrhea. Evaluate for other causes if symptoms persist. (<linkHtml href="#ID56">5.9</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID36">
                     <id root="56378d8b-3a89-4945-9d95-3ed72b947bb4"/>
                     <title>5.1 Thromboembolic and Other Vascular Conditions</title>
                     <text>
                        <list listType="unordered" ID="ID37" styleCode="Disc">
                           <item>Stop Daysee if an arterial or deep venous thrombotic/thrombembolic event occurs.</item>
                           <item>Stop Daysee if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions and evaluate for retinal vein thrombosis immediately.</item>
                           <item>Discontinue Daysee during prolonged immobilization. If feasible, stop Daysee at least 4 weeks before and through 2 weeks after major surgery, or other surgeries known to have an elevated risk of thromboembolism.</item>
                           <item>Start Daysee no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum thromboembolism decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week.</item>
                           <item>Before starting Daysee evaluate any past medical history or family history of thrombotic or thromboembolic disorders and consider whether the history suggests an inherited or acquired hypercoagulopathy. Daysee is contraindicated in women with a high risk of arterial or venous/thromboembolic diseases <content styleCode="italics">[see Contraindications (4)]</content>.</item>
                        </list>
                        <paragraph ID="ID38">
                           <content styleCode="underline">Arterial Events </content>
                        </paragraph>
                        <paragraph>COCs increase the risk of cardiovascular events and cerebrovascular events, such as myocardial infarction and stroke. The risk is greater among older women (&gt; 35 years of age), smokers, and females with hypertension, dyslipidemia, diabetes, or obesity.</paragraph>
                        <paragraph>Daysee is contraindicated in women over 35 years of age who smoke <content styleCode="italics">[see Contraindications (4)]</content>. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Venous Events </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Use of COCs increases the risk of venous thromboembolic events (VTEs), such as deep vein thrombosis and pulmonary embolism. Risk factors for VTEs include smoking, obesity, and family history of VTE, in addition to other factors that contraindicate use of CHCs</content> <content styleCode="italics">[see Contraindications (4)]</content>. While the increased risk of VTE associated with use of COCs is well-established, the rates of VTE are even greater during pregnancy, and especially during the postpartum period (see Figure 1). The rate of VTE in females using COCs has been estimated to be 3 to 9 cases per 10,000 woman years.</paragraph>
                        <paragraph>The risk of VTE is highest during the first year of use of a COC and when restarting hormonal contraception after a break of four weeks or longer. The risk of thromboembolic disease due to COCs gradually disappears after COC use is discontinued.</paragraph>
                        <paragraph>Figure 1 shows the risk of developing a VTE for women who are not pregnant and do not use oral contraceptives, for women who use oral contraceptives, and for women in the postpartum period. To put the risk of developing a VTE into perspective: If 10,000 women who are not pregnant and do not use oral contraceptives are followed for one year, between 1 and 5 of these women will develop a VTE.</paragraph>
                        <renderMultiMedia referencedObject="MM1"/>
                        <paragraph ID="ID40">Use of Daysee provides women with more hormonal exposure on a yearly basis than conventional monthly oral contraceptives containing the same strength synthetic estrogens and progestins (an additional 9 and 13 weeks of exposure to progestin and estrogen, respectively, per year).</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
               <component>
                  <section ID="ID41">
                     <id root="fc1c4c9b-2c59-416e-a48c-1dcd009c22e2"/>
                     <title>5.2 Liver Disease</title>
                     <text>
                        <paragraph ID="ID42">
                           <content styleCode="underline">Elevated Liver Enzymes </content>
                        </paragraph>
                        <paragraph>Daysee is contraindicated in women with acute viral hepatitis or severe (decompensated) cirrhosis of the liver <content styleCode="italics">[see Contraindications (4)]</content>. Acute liver test abnormalities may necessitate the discontinuation of Daysee until the liver tests return to normal and Daysee causation has been excluded. Discontinue Daysee if jaundice develops.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Liver Tumors</content>
                           </content>
                        </paragraph>
                        <paragraph>Daysee is contraindicated in women with benign or malignant liver tumors <content styleCode="italics">[see Contraindications (4)]</content>. COCs increase the risk of hepatic adenomas. An estimate of the attributable risk is 3.3 cases/100,000 COC users. Rupture of hepatic adenomas may cause death from abdominal hemorrhage.</paragraph>
                        <paragraph>Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (&gt; 8 years) COC users. The attributable risk of liver cancers in COC users is less than one case per million users.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID43">
                     <id root="b139bc4d-1ede-4193-934c-8fc9330d6111"/>
                     <title>5.3 Hypertension</title>
                     <text>
                        <paragraph ID="ID44">Daysee is contraindicated in women with uncontrolled hypertension or hypertension with vascular disease <content styleCode="italics">[see Contraindications (4)]</content>. For all women, including those with well-controlled hypertension, monitor blood pressure at routine visits and stop Daysee if blood pressure rises significantly.</paragraph>
                        <paragraph>An increase in blood pressure has been reported in women taking COCs, and this increase is more likely in older women and with extended duration of use. The effect of COCs on blood pressure may vary according to the progestin in the COC.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID45">
                     <id root="33a9c2cf-cff6-4ab2-a60c-985fa2ca60cf"/>
                     <title>5.4 Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment</title>
                     <text>
                        <paragraph ID="ID46">During clinical trials with the Hepatitis C combination drug regimen that contains obmitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications, such as Daysee. Discontinue Daysee prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir <content styleCode="italics">[see Contraindications (4)]</content>. Daysee can be restarted approximately 2 weeks following completion of treatment with the Hepatitis C combination drug regimen.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID47">
                     <id root="e702e6d1-b9cf-4e18-b054-e15e214d683d"/>
                     <title>5.5 Age-related Considerations</title>
                     <text>
                        <paragraph ID="ID48">The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increases with age. Certain conditions, such as smoking and migraine headache without aura, that do not contraindicate COC use in younger females, are contraindications to use in women over 35 years of age <content styleCode="italics">[see Contraindications (4) and Warnings and Precautions (5.1)]</content>. Consider the presence of underlying risk factors that may increase the risk of cardiovascular disease or VTE, particularly before initiating a COC for women over 35 years, such as:</paragraph>
                        <list listType="unordered" ID="ID49" styleCode="Disc">
                           <item>Hypertension</item>
                           <item>Diabetes</item>
                           <item>Dyslipidemia</item>
                           <item>Obesity</item>
                        </list>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID50">
                     <id root="2bf53785-b36e-49ab-b00b-3a9f1b7a4e6f"/>
                     <title>5.6 Gallbladder Disease</title>
                     <text>
                        <paragraph ID="ID51">Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs, including Daysee, may also worsen existing gallbladder disease.</paragraph>
                        <paragraph>A past history of COC-related cholestasis predicts an increased risk with subsequent COC use. Females with a history of pregnancy-related cholestasis may be at an increased risk for COC-related cholestasis.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID52">
                     <id root="e5d13d92-82ba-41fa-94c4-8934ad9697e7"/>
                     <title>5.7 Adverse Carbohydrate and Lipid Metabolic Effects</title>
                     <text>
                        <paragraph ID="ID53">
                           <content styleCode="underline">Hyperglycemia</content>
                        </paragraph>
                        <paragraph>Daysee is contraindicated in diabetic women over age 35, or females who have diabetes with hypertension, nephropathy, retinopathy, neuropathy, other vascular disease, or females with diabetes of &gt; 20 years duration <content styleCode="italics">[see Contraindications (4)]</content>. Daysee may decrease glucose tolerance. Carefully monitor prediabetic and diabetic women who are taking Daysee.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Dyslipidemia</content>
                        </paragraph>
                        <paragraph>Consider alternative contraception for women with uncontrolled dyslipidemia. Daysee may cause adverse lipid changes.</paragraph>
                        <paragraph>Women with hypertriglyceridemia, or a family history thereof, may have an increase in serum triglyceride concentrations when using Daysee, which may increase  the risk of pancreatitis.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID54">
                     <id root="949041b1-3a64-4c23-8e2a-ed90d3da47db"/>
                     <title>5.8 Headache</title>
                     <text>
                        <paragraph ID="ID55">Daysee is contraindicated in females who have headaches with focal neurological symptoms or have migraine headaches with aura, and in women over 35 years of age who have migraine headaches with or without aura <content styleCode="italics">[see Contraindications (4)]</content>.</paragraph>
                        <paragraph>If a woman taking Daysee develops new headaches that are recurrent, persistent, or severe, evaluate the cause and discontinue Daysee if indicated.</paragraph>
                        <paragraph>Consider discontinuation of Daysee if there is an increased frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event).</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID56">
                     <id root="3472767d-3e55-41fe-8dca-1a4796c1fcf1"/>
                     <title>5.9 Bleeding Irregularities and Amenorrhea</title>
                     <text>
                        <paragraph ID="ID57">
                           <content styleCode="underline">Unscheduled Bleeding and Spotting </content>
                        </paragraph>
                        <paragraph>Women using Daysee may experience unscheduled (breakthrough or intracyclic) bleeding and spotting, especially during the first 3 months of use. Bleeding irregularities may resolve over time or by changing to a different contraceptive product. If unscheduled bleeding persists or occurs after previously regular cycles, evaluate for causes such as pregnancy or malignancy. </paragraph>
                        <paragraph>When prescribing Daysee, the occurrence of fewer planned menses (4 per year instead of 13 per year) should be weighed against the occurrence of increased unscheduled bleeding and/or spotting. The primary clinical trial (PSE-301) that evaluated the efficacy of Daysee also assessed unscheduled bleeding. The participants in the 12-month clinical trial (N=1,006) completed the equivalent of 8,681 28-day cycles of exposure and were composed primarily of women who had used oral contraceptives previously (89%) as opposed to new users (11%). A total of 82 (8.2%) of the women discontinued Daysee, at least in part, due to bleeding or spotting.</paragraph>
                        <paragraph>Scheduled (withdrawal) bleeding and/or spotting remained fairly constant over time, with an average of 3 days of bleeding and/or spotting per each 91-day cycle. Unscheduled bleeding and unscheduled spotting decreased over successive 91-day cycles. Table 1 below presents the number of days with unscheduled bleeding in treatment cycles 1 and 4. Table 2 presents the number of days with unscheduled spotting in treatment cycles 1 and 4.</paragraph>
                        <table ID="ID58" width="99%" styleCode="Noautorules">
                           <caption>  Table 2: Total Number of Days with Unscheduled Bleeding </caption>
                           <col width="23%"/>
                           <col width="9%"/>
                           <col width="12%"/>
                           <col width="10%"/>
                           <col width="10%"/>
                           <col width="34%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">Q1 = Quartile 1: 25% of women had this number of days of unscheduled bleeding </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">Median: 50% of women had ≤ this number of days of unscheduled bleeding </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">Q3 = Quartile 3: 75% of women had ≤ this number of days of unscheduled bleeding</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> 91-Day Treatment Cycle</content>
                                    <br/>
                                 </td>
                                 <td colspan="4" valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Days per 84-Day Interval</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Days per 28-Day Interval</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Q1</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Median</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Q3</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Mean</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Mean</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 1<sup>st</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 1<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 10<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 6.9<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 1.7<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 4<sup>th</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 0<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 1<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 3.2<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 0.8<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="ID59" width="99%" styleCode="Noautorules">
                           <caption>  Table 3: Total Number of Days with Unscheduled Spotting </caption>
                           <col width="23%"/>
                           <col width="9%"/>
                           <col width="12%"/>
                           <col width="10%"/>
                           <col width="10%"/>
                           <col width="34%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">Q1 = Quartile 1: 25% of women had ≤ this number of days of unscheduled spotting</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">Median: 50% of women had ≤ this number of days of unscheduled spotting </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">Q3 = Quartile 3: 75% of women had ≤ this number of days of unscheduled spotting</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> 91-Day Treatment Cycle</content>
                                    <br/>
                                 </td>
                                 <td colspan="4" valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Days per 84-Day Interval</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Days per 28-Day Interval</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Q1</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Median</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Q3</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Mean</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Mean</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 1<sup>st</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 1<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 11<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 7.4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 1.9<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 4<sup>th</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 0<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 2<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 7<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 4.4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 1.1<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID60">Figure 2 shows the percentage of Daysee subjects participating in trial PSE-301 with ≥ 7 days or ≥ 20 days of unscheduled bleeding and/or spotting, or only unscheduled bleeding, during each 91-day treatment cycle.</paragraph>
                        <paragraph>Figure 2: Percent of Women Taking Daysee who Reported Unscheduled Bleeding and/or Spotting or only Unscheduled Bleeding </paragraph>
                        <renderMultiMedia referencedObject="MM2"/>
                        <paragraph ID="ID62">If unscheduled spotting or bleeding occurs, instruct the patient to continue on the same regimen. If the bleeding is persistent or prolonged, advise the patient to consult her healthcare provider.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Amenorrhea and Oligomenorrhea</content>
                        </paragraph>
                        <paragraph>Women who use Daysee may experience absence of scheduled (withdrawal) bleeding, even if they are not pregnant.</paragraph>
                        <paragraph>If scheduled bleeding does not occur, consider the possibility of pregnancy.</paragraph>
                        <paragraph>After discontinuation of Daysee, amenorrhea or oligomenorrhea may occur, especially if these conditions were pre-existent.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="ID63">
                     <id root="c732ab98-d957-4e96-9682-ea9f0ecd9bda"/>
                     <title>5.10 Depression</title>
                     <text>
                        <paragraph ID="ID64">Carefully observe women with a history of depression and discontinue Daysee if depression recurs to a serious degree. Data on the association of COCs with the onset of depression or exacerbation of existing depression are limited.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID65">
                     <id root="5e51cbc2-6e6e-4ad4-80b6-ad7423dca7f8"/>
                     <title>5.11 Malignant Neoplasms</title>
                     <text>
                        <paragraph ID="ID66">
                           <content styleCode="italics">Breast Cancer</content>
                        </paragraph>
                        <paragraph>Daysee is contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally sensitive <content styleCode="italics">[see Contraindications (4)].</content>
                        </paragraph>
                        <paragraph>Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk. Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer. However, some studies report a small increase in the risk of breast cancer among current or recent users (&lt;6 months since last use) and current users with longer duration of COC use <content styleCode="italics">[see Postmarketing Experience (6.2)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cervical Cancer</content>
                        </paragraph>
                        <paragraph>Some studies suggest that COCs are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there is controversy about the extent to which these findings are due to differences in sexual behavior and other factors.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID67">
                     <id root="c096c482-2c35-424d-97ec-84566cd61d79"/>
                     <title>5.12 Effect on Binding Globulins</title>
                     <text>
                        <paragraph ID="ID68">The estrogen component of Daysee may raise the serum concentrations of thyroxine-binding globulin, sex hormone-binding globulin, and cortisol-binding globulin. The dose of replacement thyroid hormone or cortisol therapy may need to be increased.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="ID69">
                     <id root="753469b4-74b3-4846-8456-a44eeeae80a4"/>
                     <title>5.13 Hereditary Angioedema</title>
                     <text>
                        <paragraph ID="ID70">In females with hereditary angioedema, exogenous estrogens, including Daysee, may induce or exacerbate symptoms of hereditary angioedema.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID71">
                     <id root="58170ca4-3050-487e-a89e-620e7ed23b00"/>
                     <title>5.14 Chloasma</title>
                     <text>
                        <paragraph ID="ID72">Chloasma may occur with Daysee use, especially in women with a history of chloasma gravidarum. Advise women with a history of chloasma to avoid exposure to the sun or ultraviolet radiation while  using Daysee.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="MM1">
                     <text>Figure 1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="9d52f9d2-f66b-4457-8cb7-c48a6e7d076f-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Figure 2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="9d52f9d2-f66b-4457-8cb7-c48a6e7d076f-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID75">
               <id root="bb5976fd-3a1c-4ef4-b20c-5835e7265490"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID76">The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling:</paragraph>
                  <list listType="unordered" ID="ID77" styleCode="Disc">
                     <item>Serious cardiovascular events and stroke [see Boxed Warning and Warnings and Precautions (5.1)]</item>
                     <item>Vascular events [see Warnings and Precautions (5.1)]</item>
                     <item>Liver disease [see Warnings and Precautions (5.2)]</item>
                  </list>
               </text>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID85">The most common adverse reactions (≥5%) in clinical trials for Daysee are irregular and/or heavy uterine bleeding, weight gain, and acne. (<linkHtml href="#ID75">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch</content>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID78">
                     <id root="8548f0ae-0b98-4c3a-b5e7-085c8ccb0145"/>
                     <title>6.1 Clinical Trial Experience</title>
                     <text>
                        <paragraph ID="ID79">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The clinical trial that evaluated the safety and efficacy of Daysee was a 12-month, randomized, multicenter, open-label study, which enrolled women aged 18 to 40, of whom 1,006 took at least one dose of Daysee.</paragraph>
                        <paragraph>Adverse Reactions Leading to Study Discontinuation: 16.3% of the women discontinued from the clinical trial due to an adverse reaction; the most common adverse reactions (≥ 1% of women) leading to discontinuation were irregular and/or heavy uterine bleeding (5.9%), weight gain (2.4%), mood changes (1.5%), and acne (1.0%).</paragraph>
                        <paragraph>Common Treatment-Emergent Adverse Reactions (≥ 5% of women) : irregular and/or heavy uterine bleeding (17%), weight gain (5%), acne (5%).</paragraph>
                        <paragraph>Serious Adverse Reactions: migraine, cholecystitis, cholelithiasis, pancreatitis, abdominal pain, and major depressive disorder.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID80">
                     <id root="8519707c-090a-4e2e-b7d6-b92f4d78fd2b"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph ID="ID81">Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 to 1.12 (Figure 3).</paragraph>
                        <paragraph>Three studies compared breast cancer risk between current or recent COC users (&lt;6 months since last use) and never users of COCs (Figure 3). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8-10 years of COC use.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 3: Relevant Studies of Risk of Breast Cancer with Combined Oral Contraceptives</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM3"/>
                        <paragraph ID="ID83">RR = relative risk; OR = odds ratio; HR = hazard ratio. "ever COC" are females with current or past COC use; "never COC use" are females that never used COCs.</paragraph>
                        <paragraph>The following adverse reactions have been identified during post-approval use of Daysee. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency of establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal </content>
                           <content styleCode="italics">disorders</content>: abdominal distension, vomiting</paragraph>
                        <paragraph>
                           <content styleCode="italics">General disorders and administration site conditions: </content>Chest pain, fatigue, malaise, edema peripheral, pain</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune </content>system disorders: hypersensitivity reaction </paragraph>
                        <paragraph>
                           <content styleCode="italics">Investigations</content>: blood pressure increased</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and connective tissue disorders</content>: muscle spasms, pain in extremity</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous system disorders</content>: dizziness, loss of consciousness</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric disorders</content>: insomnia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Reproductive and breast disorders</content>: dysmenorrhea</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, thoracic and mediastinal disorders</content>: pulmonary embolism, pulmonary thrombosis</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and subcutaneous tissue disorders</content>: alopecia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular disorders</content>: thrombosis</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Figure 3</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="9d52f9d2-f66b-4457-8cb7-c48a6e7d076f-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID86">
               <id root="7e454cf5-6991-4d89-a6d1-16bb9a792834"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph ID="ID87">The sections below provide information on substances for which data on drug interactions with COCs are available. There is little information available about the clinical effect of most drug interactions that may affect COCs. However, based on the known pharmacokinetic effects of these drugs, clinical strategies to minimize any potential adverse effect on contraceptive effectiveness or safety are suggested.</paragraph>
                  <paragraph>Consult the approved product labeling of all concurrently used drugs to obtain further information about interactions with COCs or the potential for metabolic enzyme or transporter system alterations.</paragraph>
                  <paragraph>No drug-drug interaction studies were conducted with Daysee.</paragraph>
               </text>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID100">Enzyme inducers (e.g., CYP3A4): May decrease the effectiveness of Daysee or increase breakthrough bleeding. Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with Daysee. (<linkHtml href="#ID88">7.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID88">
                     <id root="1d49a816-fa01-46dd-961f-2fe7fc469c99"/>
                     <title>7.1 Effects of Other Drugs on Combined Oral Contraceptives</title>
                     <text>
                        <paragraph ID="ID89">
                           <content styleCode="underline">Substances Decreasing the Plasma Concentrations of COCs and Potentially Diminishing the Efficacy of COCs: </content>
                        </paragraph>
                        <paragraph>Table 4 includes substances that demonstrated an important drug interaction with Daysee.</paragraph>
                        <table ID="ID90" width="640" styleCode="Noautorules">
                           <caption>  Table 4:      Significant Drug Interactions Involving Substances That Affect COCs </caption>
                           <col width="176"/>
                           <col width="464"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left"> Metabolic Enzyme Inducers<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Clinical effect<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">            Concomitant use of COCs with metabolic enzyme inducers may decrease the plasma concentrations of the estrogen and/or progestin component of COCs.<br/>            Decreased exposure of the estrogen and/or progestin component of COCs may potentially diminish the effectiveness of COCs and may lead to contraceptive failure or an increase in breakthrough bleeding.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Prevention or management<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">            Counsel females to use an alternative method of contraception or a backup method when enzyme inducers are used with COCs.<br/>            Continue backup contraception for 28 days after discontinuing the enzyme inducer to maintain contraceptive reliability.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Examples<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Aprepitant, barbiturates, bosentan, carbamazepine, efavirenz, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, rifabutin, rufinamide, topiramate, products containing St. John's wort<footnote ID="ID900">Induction potency of St. John's wort may vary widely based on preparation.</footnote>, and certain protease inhibitors (see separate section on protease inhibitors below).<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left"> Colesevelam<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Clinical effect<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">            Concomitant use of COCs with colesevelam significantly decreases systemic exposure of ethinyl estradiol.<br/>            Decreased exposure of the estrogen component of COCs may potentially reduce contraceptive efficacy or result in an increase in breakthrough bleeding, depending on the strength of ethinyl estradiol in the CHC.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Prevention or management<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Administer 4 or more hours apart to attenuate this drug interaction.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID91">
                           <content styleCode="underline">Substances increasing the systemic exposure of COCs: </content>
                        </paragraph>
                        <paragraph>Co-administration of atorvastatin or rosuvastatin and COCs containing ethinyl estradiol increase systemic exposure of ethinyl estradiol by approximately 20 to 25 percent. Ascorbic acid and acetaminophen may increase systemic exposure of ethinyl estradiol, possibly by inhibition of conjugation. CYP3A inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase systemic exposure of the estrogen and/or progestin component of COCs.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) protease inhibitors and non-nucleoside reverse transcriptase inhibitors: </content>
                        </paragraph>
                        <paragraph>Significant decreases in systemic exposure of the estrogen and/or progestin have been noted when COCs are co-administered with some HIV protease inhibitors (e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritonavir, and tipranavir/ritonavir), some HCV protease inhibitors (e.g., boceprevir and telaprevir), and some non-nucleoside reverse transcriptase inhibitors (e.g., nevirapine).</paragraph>
                        <paragraph>In contrast, significant increases in systemic exposure of the estrogen and/or progestin have been noted when COCs are co-administered with certain other HIV protease inhibitors (e.g., indinavir and atazanavir/ritonavir) and with other non-nucleoside reverse transcriptase inhibitors (e.g., etravirine).</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID92">
                     <id root="1aed09e9-0ac0-49b0-a8ff-7bc6d168c8ed"/>
                     <title>7.2 Effects of Combined Oral Contraceptives on Other Drugs</title>
                     <text>
                        <paragraph ID="ID93">Table 5 provides significant drug interaction information for drugs co-administered with Daysee.</paragraph>
                        <table ID="ID94" width="640" styleCode="Noautorules">
                           <caption>  Table 5:      Significant Drug Interaction Information for Drugs Co-Administered With COCs </caption>
                           <col width="176"/>
                           <col width="464"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Lamotrigine</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Clinical effect<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">         Concomitant use of COCs with lamotrigine may significantly decrease systemic exposure of lamotrigine due to induction of lamotrigine glucuronidation.<br/>         Decreased systemic exposure of lamotrigine may reduce seizure control.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Prevention or management<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Dose adjustment may be necessary. Consult the approved product labeling for lamotrigine.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Thyroid Hormone Replacement Therapy or Corticosteroid Replacement Therapy</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Clinical effect<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Concomitant use of COCs with thyroid hormone replacement therapy or corticosteroid replacement therapy may increase systemic exposure of thyroid-binding and cortisol-binding globulin <content styleCode="italics">[see Warnings and Precautions (5.12)]</content> .<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Prevention or management<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> The dose of replacement thyroid hormone or cortisol therapy may need to be increased. Consult the approved product labeling for the therapy in use <content styleCode="italics">[see Warnings and Precautions (5.12)]</content> .<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Other Drugs</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Clinical effect<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Concomitant use of COCs may decrease systemic exposure of acetaminophen, morphine, salicylic acid, and temazepam. Concomitant use with ethinyl estradiol-containing COCs may increase systemic exposure of other drugs (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole).<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Prevention or management<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> The dosage of drugs that can be affected by this interaction may need to be increased. Consult the approved product labeling for the concomitantly used drug.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID95">
                     <id root="6d6e0e8e-98e7-49ad-bb00-07cc9b799fe7"/>
                     <title>7.3 Concomitant Use with Hepatitis C Virus (HCV) Combination Therapy – Liver Enzyme Elevation</title>
                     <text>
                        <paragraph ID="ID96">Co-administration of Daysee with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir is contraindicated due to potential for ALT elevations <content styleCode="italics">[see Warning and Precautions (5.4)]</content>. Co-administration of Daysee and glecaprevir/pibrentasvir is not recommended due to potential for ALT elevations.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID97">
                     <id root="6a8150ce-8118-4a5d-b8f5-ee28bda4d2d7"/>
                     <title>7.4 Effect on Laboratory Tests</title>
                     <text>
                        <paragraph ID="ID98">The use of COCs may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID101">
               <id root="83956a10-3310-4d1a-8f53-062b13911519"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID113" styleCode="Disc">
                           <item>  Pregnancy: Discontinue if pregnancy occurs. (<linkHtml href="#ID102">8.1</linkHtml>)</item>
                           <item>  Lactation: Advise use of another method; Daysee is not recommended for nursing mothers; may decrease milk production. (<linkHtml href="#ID104">8.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID102">
                     <id root="1637f5f0-ece6-481c-b002-9876b1e7fc49"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID103">
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>There is no use for contraception in pregnancy; therefore, Daysee should be discontinued during pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to COCs before conception or during early pregnancy.</paragraph>
                        <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID104">
                     <id root="c3eff4c1-db6f-451f-90b4-3d31a980c304"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID105">Risk Summary</paragraph>
                        <paragraph>Contraceptive hormones and/or metabolites are present in human milk. COCs can reduce milk production in breastfeeding females. This reduction can occur at any time but is less likely to occur once breastfeeding is well-established. When possible, advise the nursing woman to use other methods of contraception until she discontinues breastfeeding <content styleCode="italics">[See Dosage and Administration (2.1]. </content>The developmental and health benefits of breastfeeding should be<content styleCode="underline"> </content>considered along with the mother's clinical need for Daysee and any potential adverse effects on the breastfed child from Daysee or the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID106">
                     <id root="562147ae-ec76-41c9-adef-518d910eeb54"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID107">Safety and efficacy of Daysee have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 18 as for users 18 years and older. Use of Daysee before menarche is not indicated.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID108">
                     <id root="b9acc026-f2d9-4720-8858-a279bd88a790"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID109">Daysee has not been studied in postmenopausal women and is not indicated in this population.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID110">
                     <id root="4c3349d0-fdc1-4cb1-9f89-c93f09383f06"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph ID="ID111">No studies have been conducted to evaluate the effect of hepatic disease on the disposition of Daysee. However, steroid hormones may be poorly metabolized in patients with impaired liver function. Daysee is contraindicated in females with acute hepatitis or severe decompensated cirrhosis <content styleCode="italics">[see Contraindications (4) and Warnings and Precautions (5.2</content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID114">
               <id root="57cf0b0e-9573-493b-85a6-26071d9fd73c"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID115">There have been no reports of serious ill effects from overdose of oral contraceptives, including ingestion by children. Overdosage may cause uterine bleeding in females and nausea.</paragraph>
               </text>
               <effectiveTime value="20230601"/>
            </section>
         </component>
         <component>
            <section ID="ID116">
               <id root="73c42954-7271-4b4c-b2a5-2be9cbb9c5ad"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID117">Daysee (levonorgestrel and ethinyl estradiol tablets USP, and ethinyl estradiol tablets USP) is an extended-cycle oral contraceptive consisting of 84 light blue tablets each containing 0.15 mg of levonorgestrel, a synthetic progestogen and 0.03 mg of ethinyl estradiol, and 7 mustard tablets containing 0.01 mg of ethinyl estradiol.</paragraph>
                  <paragraph>The structural formulas for the active components are:</paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
                  <paragraph ID="ID119">Levonorgestrel is chemically 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-,(17α)-, (-)-.</paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
                  <paragraph ID="ID121">Ethinyl Estradiol is 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Each light blue tablet contains the following inactive ingredients:</content> croscarmellose sodium, hypromellose, FD and C blue No. 1, FD and C yellow No. 6, iron oxide yellow, lactose anhydrous, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone and titanium dioxide.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Each mustard tablet contains the following inactive ingredients:</content> FD and C yellow No. 6, hypromellose, iron oxide yellow, lactose anhydrous, magnesium stearate, microcrystalline cellulose, polacrillin potassium, polyethylene glycol, polysorbate 80 and titanium dioxide.</paragraph>
                  <paragraph>
                     <content styleCode="bold">The Mustard Tablet <content styleCode="italics">i.e.</content> Ethinyl Estradiol Tablets USP meets USP Dissolution Test 2. </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250415"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>Levonorgestrel</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="9d52f9d2-f66b-4457-8cb7-c48a6e7d076f-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Ethinyl Estradiol</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="9d52f9d2-f66b-4457-8cb7-c48a6e7d076f-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID122">
               <id root="8ee5a6c2-972e-4788-b803-3b17d14e3151"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20230601"/>
               <component>
                  <section ID="ID123">
                     <id root="a94803a1-48f2-4bd2-94a9-161617c423aa"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID124">COCs prevent pregnancy primarily by suppressing ovulation.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
               <component>
                  <section ID="ID125">
                     <id root="856d56fc-150f-4bf9-aac0-dcb7cdd00751"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID126">Absorption</paragraph>
                        <paragraph>Ethinyl estradiol and levonorgestrel are absorbed with maximum plasma concentrations occurring within 2 hours after Daysee administration. Levonorgestrel is completely absorbed after oral administration (bioavailability nearly 100%) and is not subject to first-pass metabolism. Ethinyl estradiol is absorbed from the gastrointestinal tract but, due to first-pass metabolism in gut mucosa and liver, the bioavailability of ethinyl estradiol is approximately 43%.</paragraph>
                        <paragraph>The daily exposure to levonorgestrel and ethinyl estradiol on Day 21, corresponding to the end of a typical 3-week contraceptive regimen, and on Day 84, at the end of an extended cycle regimen, were similar. There was no additional accumulation of ethinyl estradiol after dosing a 0.03 mg ethinyl estradiol tablet during Days 84-91. The mean plasma pharmacokinetic parameters of Daysee following a single dose of one levonorgestrel/ethinyl estradiol combination tablet, for 84 days, in normal healthy women are reported in Table 6.</paragraph>
                        <table ID="ID127" width="100%" styleCode="Noautorules">
                           <caption>  Table 6: Mean Pharmacokinetic Parameters for Daysee during Daily One Tablet Dosing for 84 Days </caption>
                           <col width="14%"/>
                           <col width="35%"/>
                           <col width="25%"/>
                           <col width="23%"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> AUC</content>
                                    <content styleCode="bold">
                                       <sub>0-24 hr</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (mean ± SD)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> C<sub>max</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (mean ± SD)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> T<sub>max</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (mean ± SD)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule"/>
                                 <td colspan="3" valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Levonorgestrel</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center"> Day 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 18.2 ± 6.1 ng.hr/mL<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3.0 ± 1.0 ng/mL<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1.3 ± 0.4 hours<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center"> Day 21<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 64.4 ± 25.1 ng.hr/mL<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6.2 ± 1.6 ng/mL<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1.3 ± 0.4 hours<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center"> Day 84<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 60.2 ± 24.6 ng.hr/mL<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5.5 ± 1.6 ng/mL<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1.3± 0.3 hours<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule"/>
                                 <td colspan="3" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Ethinyl Estradiol</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center"> Day 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 509.3 ± 172.0 pg.hr/mL<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 69.8 ± 26 pg/mL<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1.5 ± 0.3 hours<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center"> Day 21<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 837.1 ± 271.2 pg.hr/mL<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 99.6± 31 pg/mL<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1.5 ± 0.3 hours<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center"> Day 84<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 791.5 ± 215.0 pg.hr/mL<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 91.3 ± 32 pg/mL<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1.6 ± 0.3 hours<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID128">The effect of food on the rate and the extent of levonorgestrel and ethinyl estradiol absorption following oral administration of Daysee has not been evaluated.</paragraph>
                        <paragraph>Distribution</paragraph>
                        <paragraph>The apparent volume of distribution of levonorgestrel and ethinyl estradiol are reported to be approximately 1.8 L/kg and 4.3 L/kg, respectively. Levonorgestrel is about 97.5 - 99% protein-bound, principally to sex hormone binding globulin (SHBG) and, to a lesser extent, serum albumin. Ethinyl estradiol is about 95 - 97% bound to serum albumin. Ethinyl estradiol does not bind to SHBG, but induces SHBG synthesis, which leads to decreased levonorgestrel clearance. Following repeated daily dosing of levonorgestrel/ethinyl estradiol oral contraceptives, levonorgestrel plasma concentrations accumulate more than predicted based on single-dose pharmacokinetics, due in part, to increased SHBG levels that are induced by ethinyl estradiol, and a possible reduction in hepatic metabolic capacity.</paragraph>
                        <paragraph>Metabolism</paragraph>
                        <paragraph>Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate and to a lesser extent, glucuronide conjugates in plasma. Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α -tetrahydrolevonorgestrel and 16β-hydroxylevonorgestrel. Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates. Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.</paragraph>
                        <paragraph>First-pass metabolism of ethinyl estradiol involves formation of ethinyl estradiol-3-sulfate in the gut wall, followed by 2-hydroxylation of a portion of the remaining untransformed ethinyl estradiol by hepatic cytochrome P-450 3A4 (CYP3A4). Levels of CYP3A4 vary widely among individuals and can explain the variation in rates of ethinyl estradiol hydroxylation.</paragraph>
                        <paragraph>Hydroxylation at the 4-, 6-, and 16- positions may also occur, although to a much lesser extent than 2-hydroxylation. The various hydroxylated metabolites are subject to further methylation and/or conjugation.</paragraph>
                        <paragraph>Excretion</paragraph>
                        <paragraph>About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates. The terminal elimination half-life for levonorgestrel after a single dose of Daysee was about 34 hours.</paragraph>
                        <paragraph>Ethinyl estradiol is excreted in the urine and feces as glucuronide and sulfate conjugates, and it undergoes enterohepatic recirculation. The terminal elimination half-life of ethinyl estradiol after a single dose of Daysee was found to be about 18 hours.</paragraph>
                        <paragraph>Race</paragraph>
                        <paragraph>The effect of race on the pharmacokinetics of Daysee has not been evaluated.</paragraph>
                     </text>
                     <effectiveTime value="20230601"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID129">
               <id root="7e53de71-d8cd-4dce-87f5-72bb8193dfc9"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250422"/>
               <component>
                  <section ID="ID130">
                     <id root="14640d70-0d64-41ff-942f-bdf65671f162"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis &amp; Mutagenesis &amp; Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID131">
                           <content styleCode="italics">[See </content>Warnings and Precautions (5.2, 5.11)].</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID132">
               <id root="c7362552-eab7-40f1-87ee-dbdb257e1962"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="ID133">In a 12-month, multicenter, randomized, open-label clinical trial, 1,006 women aged 18 to 40 were studied to assess the safety and efficacy of Daysee, completing the equivalent of 8,681 28-day cycles of exposure. The racial demographic of those enrolled was: Caucasian (80%), African-American (11%), Hispanic (5%), Asian (2%), and Other (2%). There were no exclusions for body mass index (BMI) or weight. The weight range of those women treated was 91 to 360 lbs., with a mean weight of 156 lbs. Among the women in the trial, 63% were current or recent hormonal contraceptive users, 26% were prior users (who had used hormonal contraceptives in the past but not in the 6 months prior to enrollment), and 11% were new starts. Of treated women, 14.8% were lost to follow-up, 16.3% discontinued due to an adverse event, and 12.9% discontinued by withdrawing their consent.</paragraph>
                  <paragraph>The pregnancy rate (Pearl Index [PI]) in women aged 18 to 35 years was 1.34 pregnancies per 100 women-years of use (95% confidence interval 0.54 to 2.75), based on 7 pregnancies that occurred after the onset of treatment and within 14 days after the last combination pill. Cycles in which conception did not occur, but which included the use of backup contraception, were not included in the calculation of the PI. The PI includes patients who did not take the drug correctly.</paragraph>
               </text>
               <effectiveTime value="20230601"/>
            </section>
         </component>
         <component>
            <section ID="ID134">
               <id root="72d3c26c-f345-41f9-9320-ab1b6a99b975"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph ID="ID135">
                     <content styleCode="bold">How Supplied</content>
                  </paragraph>
                  <paragraph>Daysee [levonorgestrel and ethinyl estradiol tablets USP (0.15 mg/0.03 mg) and ethinyl estradiol tablets USP (0.01 mg)] are available in Extended-Cycle Wallets each containing a 13-week supply of tablets: 84 light blue tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and 7 mustard tablets, each containing 0.01 mg of ethinyl estradiol. The light blue tablets are round, biconvex, film-coated tablets, debossed with "LU" on one side and "V21" on the other side. The mustard tablets are round, biconvex, film-coated tablets debossed with "LU" on one side and "V22" on the other side.</paragraph>
                  <paragraph>They are supplied as follows:</paragraph>
                  <paragraph>Daysee [levonorgestrel and ethinyl estradiol tablets USP (0.15 mg/0.03 mg) and ethinyl estradiol tablets USP (0.01 mg)] is available in an extended cycle wallet of 91 tablets which is packed in a pouch (NDC 68180-846-11). Such two pouches are packed in a carton (NDC 68180-846-13).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage and Handling</content>
                  </paragraph>
                  <paragraph>Store at 20° C to 25° C (68° F to 77° F); excursions permitted to 15°C to 30° C (59°F to 86° F) [See USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20230601"/>
            </section>
         </component>
         <component>
            <section ID="ID136">
               <id root="df1e2220-8b2f-41c6-9354-adb2533c7189"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID137">Advise the patient to read the FDA-approved Patient Labeling (Patient Information and Instructions for Use).</paragraph>
                  <paragraph>Counsel patients about the following information:</paragraph>
                  <paragraph>
                     <content styleCode="underline">Cigarette Smoking</content>
                     <content styleCode="italics">
                        <content styleCode="underline"> </content>
                     </content>
                  </paragraph>
                  <paragraph>Cigarette smoking increases the risk of serious cardiovascular events from COC use. Women who are over 35 years old and smoke should not use Daysee <content styleCode="italics">[see Boxed Warning and Warnings and Precautions. (5.1)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Venous Thromboembolism</content>
                  </paragraph>
                  <paragraph>Increased risk of VTE compared to non-users of COCs is greatest after initially starting a COC or restarting (following a 4-week or greater interruption in intake) the same or a different COC <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Use during Pregnancy </content>
                  </paragraph>
                  <paragraph>Instruct females to stop further intake of Daysee if pregnancy is confirmed during treatment.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Sexually Transmitted Infections </content>
                  </paragraph>
                  <paragraph>Daysee does not protect against HIV-infection (AIDS) and other sexually transmitted infections.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Dosing and Missed Pill Instructions</content>
                  </paragraph>
                  <paragraph>Patients should take one tablet daily by mouth at the same time every day. </paragraph>
                  <paragraph>Instruct patients what to do in the event pills are missed. See <content styleCode="bold">"What To Do If You Miss Pills" </content>section of FDA-Approved Instructions for Use <content styleCode="italics">[see Dosage and Administration (2.3)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Need for Additional Contraception</content>
                  </paragraph>
                  <paragraph>Postpartum females who have not yet had a period when they start Daysee need to use an additional method of contraception until they have taken a light blue tablet for 7 consecutive days <content styleCode="italics">[see Dosage and Administration (2.1)]</content>.</paragraph>
                  <paragraph>There is a need to use a back-up or alternative method of contraception when enzyme inducers are used with Daysee <content styleCode="italics">[see Drug Interactions (7.1)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Daysee may reduce breast milk production. This is less likely to occur if breastfeeding is well established. When possible, nursing women should use other methods of contraception until they have discontinued breastfeeding <content styleCode="italics">[see Use in Specific Populations (8.2)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Amenorrhea and Possible Symptoms of Pregnancy</content>
                  </paragraph>
                  <paragraph>Amenorrhea may occur. Advise patients to contact a healthcare provider in the event of amenorrhea with symptoms of pregnancy, such as morning sickness or unusual breast tenderness <content styleCode="italics">[see Warnings and Precautions (5.9)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Fertility Following Discontinuation of Daysee </content>
                  </paragraph>
                  <paragraph>Resumption of pre-treatment ovarian function is expected, generally within 8 weeks after discontinuation of Daysee.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Depression </content>
                  </paragraph>
                  <paragraph>Depressed mood and depression may occur. Women should contact their healthcare provider if mood changes and depressive symptoms occur, including shortly after initiating the treatment <content styleCode="italics">[see Warnings and Precautions (5.10)]</content>.</paragraph>
               </text>
               <effectiveTime value="20230601"/>
            </section>
         </component>
         <component>
            <section ID="ID138">
               <id root="0af0293c-3483-43d2-a1ee-54fecc87adda"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <renderMultiMedia referencedObject="MM6"/>
                  <paragraph ID="ID139">Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Pharmaceuticals, Inc.</content>
                  </paragraph>
                  <paragraph>Naples, FL 34108</paragraph>
                  <paragraph>United States.</paragraph>
                  <paragraph>Manufactured by: </paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Limited</content>
                  </paragraph>
                  <paragraph>Pithampur (M.P.) – 454 775</paragraph>
                  <paragraph>INDIA</paragraph>
                  <paragraph>Revised: October 2024</paragraph>
               </text>
               <effectiveTime value="20250415"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>trade mark</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="9d52f9d2-f66b-4457-8cb7-c48a6e7d076f-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID140">
               <id root="5fa26811-3b42-4763-a15c-c7f6de7ea0ca"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <paragraph ID="ID141">FDA-Approved Patient Labeling</paragraph>
                  <paragraph>PATIENT INFORMATION</paragraph>
                  <paragraph>Daysee™</paragraph>
                  <paragraph>(DAY-zee) </paragraph>
                  <paragraph>
                     <content styleCode="bold">[levonorgestrel and ethinyl estradiol tablets USP (0.15 mg/0.03 mg) and ethinyl estradiol tablets USP (0.01 mg)]</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250415"/>
               <component>
                  <section ID="ID142">
                     <id root="1838ec74-6068-405a-8f1e-fd48989e5d2f"/>
                     <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
                     <text>
                        <paragraph ID="ID143">WARNING TO WOMEN WHO SMOKE</paragraph>
                        <paragraph>Do not use Daysee if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.</paragraph>
                     </text>
                     <effectiveTime value="20230627"/>
                  </section>
               </component>
               <component>
                  <section ID="ID144">
                     <id root="7a48947b-f833-4790-8780-c6c8232d1dfe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID145">
                           <content styleCode="bold">What is the most important information I should know about Daysee?</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Do not use Daysee if you smoke cigarettes and are over 35 years old. </content>Smoking increases your risk of serious cardiovascular side effects from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.</paragraph>
                        <paragraph>
                           <content styleCode="bold">What is Daysee?</content>
                        </paragraph>
                        <paragraph>Daysee is a birth control pill (hormonal contraceptive) used by women to prevent pregnancy. It contains two female hormones, an estrogen called ethinyl estradiol, and a progestin called levonorgestrel.</paragraph>
                        <paragraph>Daysee does not protect against HIV infection (AIDS) and other sexually transmitted infections.</paragraph>
                        <paragraph>
                           <content styleCode="bold">How Does Daysee Work for contraception?</content>
                        </paragraph>
                        <paragraph>Your chance of getting pregnant depends on how well you follow the directions for taking your birth control pills. The more carefully you follow the directions, the less chance you have of getting pregnant.</paragraph>
                        <paragraph>Based on the results of a single clinical study lasting 12 months, 1 to 3 women, out of 100 women, may get pregnant during the first year they use Daysee.</paragraph>
                        <paragraph>The following chart shows the chance of getting pregnant for women who use different methods of birth control. Each box on the chart contains a list of birth control methods that are similar in effectiveness. The most effective methods are at the top of the chart. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant.</paragraph>
                        <renderMultiMedia referencedObject="MM7"/>
                        <paragraph ID="ID147">
                           <content styleCode="bold">Who Should Not Take Daysee? </content>
                        </paragraph>
                        <paragraph>Do not take Daysee if you: </paragraph>
                        <list listType="unordered" ID="ID148" styleCode="Disc">
                           <item>smoke and are over 35 years of age</item>
                           <item>have or had blood clots in your arms, legs, eyes or lungs</item>
                           <item>had a stroke</item>
                           <item>had a heart attack</item>
                           <item>have certain heart valve problems or heart rhythm abnormalities that can cause blood clots to form in the heart</item>
                           <item>have or had a problem with your blood that makes it clot more than normal</item>
                           <item>have high blood pressure that cannot be controlled by medicine or have high blood pressure with blood vessel problems</item>
                           <item>have diabetes and are over the age of 35; have diabetes with high blood pressure; kidney, eye, nerve, or blood vessel damage; or for more than 20 years</item>
                           <item>have certain kinds of severe migraine headaches with aura, numbness, weakness or changes in vision, or any migraine headaches if you are over the age of 35</item>
                           <item>have or had breast cancer</item>
                           <item>have liver disease, including liver tumors</item>
                           <item>have unexplained vaginal bleeding</item>
                           <item>take any Hepatitis C drug combination containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This may increase levels</item>
                        </list>
                        <paragraph ID="ID149">Birth control pills may not be a good choice for you if you have ever had jaundice (yellowing of the skin or eyes) caused by pregnancy. </paragraph>
                        <paragraph>
                           <content styleCode="bold">If any of these conditions happen to you while you are taking Daysee, stop taking Daysee right away and talk to your healthcare provider. Use non-hormonal contraception when you stop taking Daysee. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">What should I tell my healthcare provider before taking Daysee?</content>
                        </paragraph>
                        <paragraph>Tell your healthcare provider if you:</paragraph>
                        <list listType="unordered" ID="ID150" styleCode="Disc">
                           <item>are pregnant or think you may be pregnant</item>
                           <item>are scheduled for surgery. Daysee may increase your risk of blood clots after surgery. You should stop taking Daysee at least 4 weeks before you have surgery and not restart Daysee until at least 2 weeks after your surgery.</item>
                           <item>are depressed now or have been depressed in the past</item>
                           <item>had yellowing of your skin or eyes (jaundice) caused by pregnancy (cholestasis of pregnancy)</item>
                           <item>are breastfeeding or plan to breastfeed. Daysee may decrease the amount of breast milk you make. A small amount of the hormones in Daysee may pass into your breast milk. Talk to your healthcare provider about the best birth control method for you while breastfeeding.</item>
                        </list>
                        <paragraph ID="ID151">Tell your healthcare provider if you have ever had any of the conditions listed in, "<content styleCode="bold">Who should not take Daysee" above. </content>Your healthcare provider may recommend another method of birth control. </paragraph>
                        <paragraph>Tell your healthcare provider about all medicines and herbal products that you take. Some medicines and herbal products may make birth control pills less effective, including:</paragraph>
                        <list listType="unordered" ID="ID152" styleCode="Disc">
                           <item>barbiturates</item>
                           <item>bosentan</item>
                           <item>carbamazepine</item>
                           <item>felbamate</item>
                           <item>griseofulvin</item>
                           <item>oxcarbazepine</item>
                           <item>phenytoin</item>
                           <item>rifampin</item>
                           <item>St. John's wort</item>
                           <item>Topiramate</item>
                        </list>
                        <paragraph ID="ID153">Use a back-up or alternative birth control method when you take medicines that may make birth control pills less effective.</paragraph>
                        <paragraph>Birth control pills may interact with lamotrigine, an anticonvulsant used for epilepsy. This may increase the risk of seizures, so your physician may need to adjust the dose of lamotrigine.</paragraph>
                        <paragraph>Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone.</paragraph>
                        <paragraph>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                        <paragraph>
                           <content styleCode="bold">How should I take Daysee? </content>
                        </paragraph>
                        <paragraph>Read the <content styleCode="bold">Instructions for Use</content> at the end of this Patient Information. </paragraph>
                        <paragraph>
                           <content styleCode="bold">What are the most serious risks of taking birth control pills?</content>
                        </paragraph>
                        <paragraph>Like pregnancy, birth control pills increase the risk of serious blood clots, especially in women who have other risk factors, such as smoking, obesity, or age over 35 years old. It is possible to die from a problem caused by a blood clot, such as a heart attack or a stroke. Some examples of serious blood clots are blood clots in the:</paragraph>
                        <list listType="unordered" ID="ID154" styleCode="Disc">
                           <item>Legs (thrombophlebitis)</item>
                           <item>Lungs (pulmonary embolus)</item>
                           <item>Eyes (loss of eyesight)</item>
                           <item>Heart (heart attack)</item>
                           <item>Brain (stroke)</item>
                        </list>
                        <paragraph ID="ID155">Women who take birth control pills may get: </paragraph>
                        <list listType="unordered" ID="ID156" styleCode="Disc">
                           <item>High blood pressure. You should see your healthcare provider to check your blood pressure regularly.</item>
                           <item>Gallbladder problems</item>
                           <item>Rare cancerous or noncancerous liver tumors</item>
                        </list>
                        <paragraph ID="ID157">All of these events are uncommon in healthy women. </paragraph>
                        <paragraph>Call your healthcare provider right away if you have: </paragraph>
                        <list listType="unordered" ID="ID158" styleCode="Disc">
                           <item>Persistent leg pain</item>
                           <item>Sudden shortness of breath</item>
                           <item>Sudden blindness, partial or complete</item>
                           <item>Severe pain in your chest</item>
                           <item>Sudden, severe headache unlike your usual headaches</item>
                           <item>Weakness or numbness in an arm or leg, or trouble speaking</item>
                           <item>Yellowing of the skin or eyeballs</item>
                        </list>
                        <paragraph ID="ID159">
                           <content styleCode="bold">What are common side effects of birth control pills? </content>
                        </paragraph>
                        <paragraph>The most common side effects of birth control pills are: </paragraph>
                        <list listType="unordered" ID="ID160" styleCode="Disc">
                           <item>Spotting or bleeding between menstrual periods</item>
                           <item>Nausea</item>
                           <item>Breast tenderness</item>
                           <item>Headache</item>
                        </list>
                        <paragraph ID="ID161">These side effects are usually mild and usually disappear with time. Less common side effects are: </paragraph>
                        <list listType="unordered" ID="ID162" styleCode="Disc">
                           <item>Acne</item>
                           <item>Less sexual desire</item>
                           <item>Bloating or fluid retention</item>
                           <item>Blotchy darkening of the skin, especially on the face</item>
                           <item>High blood sugar, especially in women who already have diabetes</item>
                           <item>High fat levels in the blood</item>
                           <item>Depression, especially if you have had depression in the past. Call your healthcare provider immediately if you have any thoughts of harming yourself.</item>
                           <item>Problems tolerating contact lenses</item>
                           <item>Weight changes</item>
                        </list>
                        <paragraph ID="ID163">This is not a complete list of possible side effects. Talk to your healthcare provider if you develop any side effects that concern you. You may report side effects to the FDA at 1-800-FDA-1088. </paragraph>
                        <paragraph>No serious problems have been reported from a birth control pill overdose, even when accidentally taken by children. </paragraph>
                        <paragraph>
                           <content styleCode="bold">What else should I know about taking Daysee? </content>
                        </paragraph>
                        <list listType="unordered" ID="ID164" styleCode="Disc">
                           <item>If you are scheduled for any lab tests, tell your healthcare provider you are taking Daysee. Certain blood tests may be affected by Daysee.</item>
                           <item>Do not skip any pills, even if you do not have sex often.</item>
                           <item>Birth control pills should not be taken during pregnancy. However, birth control pills taken by accident during pregnancy are not known to cause birth defects.</item>
                           <item>You should stop Daysee at least four weeks before you have major surgery and not restart it for at least two weeks after the surgery, due to an increased risk of blood clots.</item>
                           <item>If you are breastfeeding, consider another birth control method until you are ready to stop breastfeeding. Birth control pills that contain estrogen, like Daysee, may decrease the amount of milk you make. A small amount of the pill's hormones pass into breast milk.</item>
                           <item>If you have vomiting or diarrhea, your birth control pills may not work as well. Use another birth control method, like condoms or a spermicide, until you check with your healthcare provider.</item>
                        </list>
                        <paragraph ID="ID165">
                           <content styleCode="bold">How should I store Daysee? </content>
                        </paragraph>
                        <list listType="unordered" ID="ID166" styleCode="Disc">
                           <item>Store Daysee at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                           <item>Keep Daysee and all medicines out of the reach of children.</item>
                        </list>
                        <paragraph ID="ID167">
                           <content styleCode="bold">General information about Daysee </content>
                        </paragraph>
                        <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Daysee for a condition for which it was not prescribed. Do not give Daysee to anyone else. </paragraph>
                        <paragraph>This Patient Information summarizes the most important information about Daysee. If you have concerns or questions, ask your healthcare provider. You may also ask your healthcare providers for a more detailed label written for medical professionals. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Do birth control pills cause cancer? </content>
                        </paragraph>
                        <paragraph>It is not known if hormonal birth control pills cause breast cancer. Some studies, but not all, suggest that there could be a slight increase in the risk of breast cancer among current users with longer duration of use. </paragraph>
                        <paragraph>If you have breast cancer now, or have had it in the past, do not use hormonal birth control because some breast cancers are sensitive to hormones. Women who use birth control pills may have a slightly higher chance of getting cervical cancer. However, this may be due to other reasons such as having more sexual partners. </paragraph>
                        <paragraph>
                           <content styleCode="bold">What if I want to become pregnant? </content>
                        </paragraph>
                        <paragraph>You may stop taking the pill whenever you wish. Consider a visit with your healthcare provider for a pre-pregnancy checkup before you stop taking the pill. </paragraph>
                        <paragraph>
                           <content styleCode="bold">What should I know about my period when taking Daysee? </content>
                        </paragraph>
                        <paragraph>When you take Daysee, which has a 91-day extended dosing cycle, you should expect to have 4 scheduled periods per year (bleeding when you are taking the 7 mustard pills). Each period is likely to last about 3 days. However, you will probably have more bleeding or spotting between your scheduled periods than if you were using a birth control pill with a 28-day dosing cycle. During the first Daysee 91-day treatment cycle, about 3 in 10 women may have 20 or more days of unplanned bleeding or spotting. This bleeding or spotting tends to decrease with time. Do not stop taking Daysee because of this bleeding or spotting. If the spotting continues for more than 7 consecutive days or if the bleeding is heavy, call your healthcare provider. </paragraph>
                        <paragraph>
                           <content styleCode="bold">What if I miss my scheduled period when taking Daysee? </content>
                        </paragraph>
                        <paragraph>You should consider the possibility that you are pregnant if you miss your scheduled period (no bleeding on the days that you are taking mustard tablets). Since scheduled periods are less frequent when you are taking Daysee, notify your healthcare provider that you have missed your period and that you are taking Daysee. Also notify your healthcare provider if you have symptoms of pregnancy such as morning sickness or unusual breast tenderness. It is important that your healthcare provider evaluates you to determine if you are pregnant. Stop taking Daysee if it is determined that you are pregnant. </paragraph>
                        <paragraph>
                           <content styleCode="bold">What are the ingredients in Daysee? </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Active ingredients:</content>
                        </paragraph>
                        <paragraph>Light blue tablets: levonorgestrel and ethinyl estradiol </paragraph>
                        <paragraph>Mustard tablets: ethinyl estradiol </paragraph>
                        <paragraph>
                           <content styleCode="bold">Inactive ingredients: </content>
                        </paragraph>
                        <paragraph>Light blue tablets: croscarmellose sodium, hypromellose, FD and C blue No. 1, FD and C yellow No. 6, iron oxide yellow, lactose anhydrous, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone and titanium dioxide. </paragraph>
                        <paragraph>Mustard tablets: FD and C yellow No. 6, hypromellose, iron oxide yellow, lactose anhydrous, magnesium stearate, microcrystalline cellulose, polacrillin potassium, polyethylene glycol, polysorbate 80 and titanium dioxide.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="9d52f9d2-f66b-4457-8cb7-c48a6e7d076f-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID168">
               <id root="08ec60d0-7183-44c1-9ad6-1a96ca68e074"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph ID="ID169">
                     <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Daysee™</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(DAY-zee) </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">[levonorgestrel and ethinyl estradiol tablets USP (0.15 mg/0.03 mg) and ethinyl estradiol tablets USP (0.01 mg)]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">How do I take Daysee? </content>
                  </paragraph>
                  <list listType="ordered" ID="ID170">
                     <item>Take one pill every day at the same time. If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant.</item>
                     <item>Many women have spotting or light bleeding or may feel sick to their stomach during the first few months of taking Daysee. If you feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your healthcare provider.</item>
                     <item>Missing pills can also cause spotting or light bleeding, even when you take the missed pills later. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach.</item>
                     <item>If you have trouble remembering to take Daysee, talk to your healthcare provider about how to make pill-taking easier or about using another method of birth control.</item>
                  </list>
                  <paragraph ID="ID171">
                     <content styleCode="bold">
                        <content styleCode="underline">Before</content> you start taking Daysee </content>
                  </paragraph>
                  <paragraph>1. Decide what time of day you want to take your pill. It is important to take it at about the same time every day. </paragraph>
                  <paragraph>2. Look at your Extended-Cycle Tablet Dispenser. Your Tablet Dispenser consists of 3 trays with cards that hold 91 individually sealed pills (a 13-week or 91-day cycle). The 91 pills consist of 84 light blue and 7 mustard pills. Trays 1 and 2 each contain 28 light blue pills (4 rows of 7 pills). Tray 3 contains 35 pills consisting of 28 light blue pills (4 rows of 7 pills) and 7 mustard pills (1 row of 7 pills). </paragraph>
                  <renderMultiMedia referencedObject="MM8"/>
                  <paragraph ID="ID173">3. Also find: </paragraph>
                  <list listType="unordered" ID="ID174" styleCode="Disc">
                     <item>Where on the first tray in the pack to start taking pills (upper left corner at the start arrow) and</item>
                     <item>In what order to take the pills (follow the weeks and arrow).</item>
                  </list>
                  <paragraph ID="ID175">4. Be sure you have ready at all times another kind of birth control (such as condoms or spermicides), to use as a back-up in case you miss pills.</paragraph>
                  <paragraph>
                     <content styleCode="bold">If you are switching from another birth control method: </content>
                  </paragraph>
                  <paragraph>If you have been using a different hormonal method of birth control (such as a different pill, the "patch," or the "vaginal ring"), you need to use another method of birth control (such as condoms or spermicides) each time you have sex after stopping your old method of birth control until you have taken Daysee for 7 days. </paragraph>
                  <paragraph>
                     <content styleCode="bold">If you have recently given birth and have not yet had a period</content>, use another method of birth control if you have sex (such as condoms and spermicides) as a back-up method until you have taken Daysee for 7 days. </paragraph>
                  <paragraph>
                     <content styleCode="bold">When to start Daysee </content>
                  </paragraph>
                  <list listType="ordered" ID="ID176">
                     <item>Take the first light blue pill on the Sunday after your period starts, even if you are still bleeding. If your period begins on Sunday, start the first light blue pill that same day.</item>
                     <item>Use another method of birth control (such as condoms or spermicides) as a back-up method if you have sex anytime from the Sunday you start your first light blue pill until the next Sunday (first 7 days). If you have been using a different hormonal method of birth control (such as a different pill, the "patch," or the "vaginal ring"), you need to use another method of birth control (such as condoms or spermicides) each time you have sex after stopping your old method of birth control until you have taken Daysee for 7 days.</item>
                  </list>
                  <paragraph ID="ID177">
                     <content styleCode="bold">How to take Daysee </content>
                  </paragraph>
                  <paragraph>1. Take one pill at the same time every day until you have taken the last pill in the tablet dispenser. </paragraph>
                  <list listType="unordered" ID="ID178" styleCode="Disc">
                     <item>Do not skip pills even if you are experiencing spotting or bleeding or feel sick to your stomach (nausea).</item>
                     <item>Do not skip pills even if you do not have sex very often.</item>
                  </list>
                  <paragraph ID="ID179">2.   When you finish a tablet dispenser </paragraph>
                  <list listType="unordered" ID="ID180" styleCode="Disc">
                     <item>After taking the last mustard pill, start taking the first light blue pill from a new Extended-Cycle Tablet Dispenser the very next day (this should be on a Sunday) regardless of when your period started.</item>
                  </list>
                  <paragraph ID="ID181">3.   If you miss your scheduled period when you are taking the mustard pills, contact your healthcare provider because you may be pregnant. If you are pregnant, you should stop taking Daysee. </paragraph>
                  <paragraph>
                     <content styleCode="bold">What to do if you miss pills </content>
                  </paragraph>
                  <paragraph>If you <content styleCode="bold">MISS 1 </content>light blue pill:</paragraph>
                  <list listType="ordered" ID="ID182">
                     <item>Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day.</item>
                     <item>You do not need to use a back-up birth control method if you have sex.</item>
                  </list>
                  <paragraph ID="ID183">If you <content styleCode="bold">MISS 2 </content>light blue pills in a row: </paragraph>
                  <list listType="ordered" ID="ID184">
                     <item>Take 2 pills on the day you remember, and 2 pills the next day.</item>
                     <item>Then take 1 pill a day until you finish the pack.</item>
                     <item>You could become pregnant if you have sex in the 7 days after you miss two pills. You MUST use another birth control method (such as condoms or spermicide) as a back up for the 7 days after you restart your pills.</item>
                  </list>
                  <paragraph ID="ID185">If you <content styleCode="bold">MISS 3 OR MORE </content>light blue pills in a row: </paragraph>
                  <list listType="ordered" ID="ID186">
                     <item>Do not take the missed pills. Keep taking 1 pill every day as indicated on the pack until you have completed all of the remaining pills in the pack. For example: If you resume taking the pill on Thursday, take the pill under "Thursday" and do not take the missed pills. You may experience bleeding during the week following the missed pills.</item>
                     <item>You could become pregnant if you have sex during the days of missed pills or during the first 7 days after restarting your pills.</item>
                     <item>You MUST use a non-hormonal birth control method (such as condoms or spermicide) as a back-up when you miss pills and for the first 7 days after you restart your pills. If you do not have your period when you are taking the mustard pills, call your healthcare provider because you may be pregnant.</item>
                  </list>
                  <paragraph ID="ID187">If you <content styleCode="bold">MISS ANY </content>of the 7 mustard pills: </paragraph>
                  <list listType="ordered" ID="ID188">
                     <item>Throw away the missed pills.</item>
                     <item>Keep taking the scheduled pills until the pack is finished.</item>
                     <item>You do not need a back-up method of birth control.</item>
                  </list>
                  <paragraph ID="ID189">
                     <content styleCode="bold">Finally, if you are still not sure what to do about the pills you have missed </content>
                  </paragraph>
                  <list listType="unordered" ID="ID190" styleCode="Disc">
                     <item>Use a back-up method anytime you have sex.</item>
                     <item>Keep taking one pill each day until you contact your healthcare provider.</item>
                  </list>
                  <paragraph ID="ID191">This Patient Information and Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
               </text>
               <effectiveTime value="20250415"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>Wallet</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="9d52f9d2-f66b-4457-8cb7-c48a6e7d076f-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID192">
               <id root="ce04985a-d1cd-46f9-9eab-285df5c226e0"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <renderMultiMedia referencedObject="MM9"/>
                  <paragraph ID="ID193">Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Pharmaceuticals, Inc.</content>
                  </paragraph>
                  <paragraph>Naples, FL 34108</paragraph>
                  <paragraph>United States.</paragraph>
                  <paragraph>Manufactured by: </paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Limited</content>
                  </paragraph>
                  <paragraph>Pithampur (M.P.) – 454 775</paragraph>
                  <paragraph>India</paragraph>
                  <paragraph>Revised: October 2024                                                                                   ID#: 278060</paragraph>
               </text>
               <effectiveTime value="20250415"/>
               <component>
                  <observationMedia ID="MM9">
                     <text>Trade mark</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="9d52f9d2-f66b-4457-8cb7-c48a6e7d076f-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID194">
               <id root="32bfdd02-8af7-4488-b8d6-3e9efa9252c5"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID195">
                     <content styleCode="bold">Daysee [levonorgestrel and ethinyl estradiol tablets USP (0.15 mg/0.03 mg) and ethinyl estradiol tablets USP (0.01 mg)]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>NDC 68180-846-11</paragraph>
                  <paragraph>Wallet Label: 91 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM10"/>
                  <paragraph ID="ID197">
                     <content styleCode="bold">Daysee [levonorgestrel and ethinyl estradiol tablets USP (0.15 mg/0.03 mg) and ethinyl estradiol tablets USP (0.01 mg)]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>NDC 68180-846-11</paragraph>
                  <paragraph>Pouch Label: 1 Extended-Cycle Wallet of 91 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM11"/>
                  <paragraph ID="ID199">
                     <content styleCode="bold">Daysee [levonorgestrel and ethinyl estradiol tablets USP (0.15 mg/0.03 mg) and ethinyl estradiol tablets USP (0.01 mg)]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>NDC 68180-846-13</paragraph>
                  <paragraph>Carton Label: 2 Extended-Cycle Wallets of 91 Tablets Each</paragraph>
                  <renderMultiMedia referencedObject="MM12"/>
               </text>
               <effectiveTime value="20250415"/>
               <component>
                  <observationMedia ID="MM10">
                     <text>Wallet Label: 91 Tablets</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="9d52f9d2-f66b-4457-8cb7-c48a6e7d076f-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM11">
                     <text>Pouch Label: 1 Extended-Cycle Wallet of 91 Tablets</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="9d52f9d2-f66b-4457-8cb7-c48a6e7d076f-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM12">
                     <text>Carton Label: 2 Extended-Cycle Wallets of 91 Tablets Each</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="9d52f9d2-f66b-4457-8cb7-c48a6e7d076f-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>